Recurrent High-Grade Glioma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Recurrent High-Grade Glioma Market Outlook
Thelansis’s “Recurrent High-Grade
Glioma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2024 To 2034" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Recurrent High-Grade Glioma
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Recurrent High-Grade Glioma Overview
Recurrence
of high-grade gliomas, including glioblastoma multiforme (grade IV) and
anaplastic astrocytoma (grade III), poses an unavoidable challenge. Despite
aggressive surgical resection of the primary tumor and subsequent adjuvant
re-chemoradiation, patients face a dismal prognosis, with a median survival of
only 11 months. Typically, recurrence manifests during MRI examinations,
revealing tumor enlargement accompanied by increased edema and a noticeable
mass effect. Currently, there is no established standard of treatment for
managing recurrent high-grade gliomas. Options such as re-resection,
re-irradiation, and chemotherapy are available, but their long-term efficacy
remains unproven. Glioblastoma recurrence typically occurs approximately 32–36
weeks after initial multimodal treatment, often due to ongoing neoplastic
growth within 2–3 cm of the original lesion.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment